- Home
- GNLX vs PROF Comparison
GNLX vs PROF Comparison
Compare GNLX & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- PROF
- Stock Information
- Founded
- GNLX 2001
- PROF N/A
- Country
- GNLX United States
- PROF Canada
- Employees
- GNLX N/A
- PROF N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- PROF Medical/Dental Instruments
- Sector
- GNLX Health Care
- PROF Health Care
- Exchange
- GNLX Nasdaq
- PROF Nasdaq
- Market Cap
- GNLX 128.0M
- PROF 149.7M
- IPO Year
- GNLX 2023
- PROF N/A
- Fundamental
- Price
- GNLX $3.78
- PROF $4.74
- Analyst Decision
- GNLX Strong Buy
- PROF Strong Buy
- Analyst Count
- GNLX 5
- PROF 1
- Target Price
- GNLX $16.20
- PROF $11.00
- AVG Volume (30 Days)
- GNLX 89.3K
- PROF 160.5K
- Earning Date
- GNLX 08-07-2025
- PROF 08-14-2025
- Dividend Yield
- GNLX N/A
- PROF N/A
- EPS Growth
- GNLX N/A
- PROF N/A
- EPS
- GNLX N/A
- PROF N/A
- Revenue
- GNLX N/A
- PROF $11,840,000.00
- Revenue This Year
- GNLX N/A
- PROF $63.99
- Revenue Next Year
- GNLX N/A
- PROF $117.19
- P/E Ratio
- GNLX N/A
- PROF N/A
- Revenue Growth
- GNLX N/A
- PROF 59.81
- 52 Week Low
- GNLX $1.95
- PROF $3.90
- 52 Week High
- GNLX $5.89
- PROF $9.71
- Technical
- Relative Strength Index (RSI)
- GNLX 62.02
- PROF 39.03
- Support Level
- GNLX $3.26
- PROF $4.31
- Resistance Level
- GNLX $3.50
- PROF $5.96
- Average True Range (ATR)
- GNLX 0.24
- PROF 0.36
- MACD
- GNLX 0.01
- PROF -0.08
- Stochastic Oscillator
- GNLX 99.47
- PROF 28.65
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.